Clinical Trial

A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

Study acronym: RESTORE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2027-06-30 2026-08-07
minor Completion pushed: 2026-09-30 -> 2027-09-30 2026-08-07
Trial Details
NCT Number NCT03862430
Lead Sponsor NuvOx LLC
Conditions Glioblastoma Multiforme
Enrollment 87 participants
Start Date 2023-03-31
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-06